FDA OKs First Tazarotene Lotion (Arazlo) for Acne Vulgaris
Arazlo is the first tazarotene acne treatment available in lotion form, and has been shown to provide strong efficacy with favorable tolerability, the company said. FDA Approvals …read more
Breast reduction surgery: Everything you need to know
Breast reduction surgery is a cosmetic procedure that can reduce the size of a person’s breasts. Learn about who can benefit and how the procedure works here. …read more
Are You Seeing Fewer Patients in Your Practice?
Two new studies suggest that the number of primary care visits in the United States is decreasing. Medscape Reader Polls …read more
Anastrozole Extends Breast Cancer Protection Once Stopped
A 5-year regimen of anastrozole protects women against new breast cancers for at least another 5 years they stop taking the drug. Medscape Medical News …read more
What can you do to reduce fibroid pain?
Uterine fibroids can be painful and disrupt daily life. Learn about what treatments and medications are available and how to ease the pain. …read more
Male scientists more likely to present findings positively
Clinical articles with male first or last authors tend to be more positive about findings than those with female first and last authors, says a new study. …read more
Omit Surgery in Early-Stage Breast Cancer? Not Yet
It’s an enticing idea in an age of breast cancer treatment de-escalation: omit surgery if a patient achieves what looks like a complete response to neoadjuvant chemotherapy. Medscape Medical News …read more
Weight gain during period: What to know
Some people may experience perceived or actual weight gain around the time of their period. Read on to find out why and how to prevent weight gain during a period. …read more
EMA Panel Backs Adalimumab Biosimilar Amsparity
The CHMP has recommended approval of Pfizer’s adalimumab biosimilar (Amsparity) for treatment of certain inflammatory and autoimmune disorders in adults and children. International Approvals …read more
Outcomes in TN Breast Cancer Predicted by Blood Biomarkers
Biomarkers of residual disease at surgery identify which triple-negative breast cancer patients already treated with neoadjuvant therapy will do well and which will do poorly over the next 2 years. Medscape Medical News …read more